Literature DB >> 30944209

Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site.

Alican Gulsevin1, Roger L Papke2, Clare Stokes1, Sumanta Garai1, Ganesh A Thakur1, Marta Quadri1, Nicole A Horenstein3.   

Abstract

Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of ligand-gated ion channels. Typically, channel activation follows the binding of agonists to the orthosteric binding sites of the receptor. α7 nAChRs have a very low probability of channel activation, which can be reversed by the binding of α7 selective positive allosteric modulators (PAMs) to putative sites within the transmembrane domains. Although typical PAMs, like PNU-120596, require coapplication of an orthosteric agonist to produce large channel activations, some, like GAT107 and B-973B [(S)-3-(3,4-difluorophenyl)-N-(1-(6-(4-(pyridin-2-yl)piperazin-1-yl)pyrazin-2-yl)ethyl)propanamide], are characterized as allosteric activating PAMs, which also bind to an allosteric activation (AA) site in the extracellular domain and activate the α7 ion channel by themselves. We had previously characterized N,N-diethyl-N'-phenylpiperazine analogs with various functions. In this work, we docked members of this family to a homology model of the α7 receptor extracellular domain. The compound 1,1-diethyl-4(naphthalene-2-yl)piperazin-1-ium (2NDEP) a weak partial agonist, showed particularly favorable docking and binding energies at the putative AA site of the receptor. We hypothesized that 2NDEP could couple with PAMs through the AA site. This hypothesis was tested with the α7 mutant C190A, which is not activated by orthosteric agonists but is effectively activated by GAT107. The results showed that 2NDEP acts as an allosteric agonist of α7C190A when coapplied with the PAM PNU-120596. Also, the allosteric activity was nearly abolished upon coapplication with the AA site-selective antagonist 2,3,5,6MP-TQS (cis-trans-4-(2,3,5,6-tetramethylphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide), consistent with AA site involvement. Overall, our findings show a novel mode of agonism through an allosteric site in the extracellular domain of α7 nAChR.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30944209      PMCID: PMC6491904          DOI: 10.1124/mol.119.115758

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

1.  A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.

Authors:  Raymond S Hurst; Mihaly Hajós; Mario Raggenbass; Theron M Wall; Nicole R Higdon; Judy A Lawson; Karen L Rutherford-Root; Mitchell B Berkenpas; W E Hoffmann; David W Piotrowski; Vincent E Groppi; Geraldine Allaman; Roch Ogier; Sonia Bertrand; Daniel Bertrand; Stephen P Arneric
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

2.  A possible desensitized state conformation of the human α7 nicotinic receptor: A molecular dynamics study.

Authors:  L Chiodo; T E Malliavin; L Maragliano; G Cottone
Journal:  Biophys Chem       Date:  2017-06-30       Impact factor: 2.352

3.  B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor.

Authors:  Debra J Post-Munson; Rick L Pieschl; Thaddeus F Molski; John D Graef; Adam W Hendricson; Ronald J Knox; Ivar M McDonald; Richard E Olson; John E Macor; Michael R Weed; Linda J Bristow; Laszlo Kiss; Michael K Ahlijanian; James Herrington
Journal:  Eur J Pharmacol       Date:  2017-01-26       Impact factor: 4.432

4.  Macroscopic and Microscopic Activation of α7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107.

Authors:  Marta Quadri; Sumanta Garai; Ganesh A Thakur; Clare Stokes; Alican Gulsevin; Nicole A Horenstein; Roger L Papke
Journal:  Mol Pharmacol       Date:  2018-10-22       Impact factor: 4.436

5.  Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist.

Authors:  Shu-Xing Li; Sun Huang; Nina Bren; Kaori Noridomi; Cosma D Dellisanti; Steven M Sine; Lin Chen
Journal:  Nat Neurosci       Date:  2011-09-11       Impact factor: 24.884

6.  Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Authors:  Jaskiran K Gill; Mari Savolainen; Gareth T Young; Ruud Zwart; Emanuele Sher; Neil S Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

7.  Working with OpusXpress: methods for high volume oocyte experiments.

Authors:  Roger L Papke; Clare Stokes
Journal:  Methods       Date:  2010-01-18       Impact factor: 3.608

8.  The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface.

Authors:  Roger L Papke; Nicole A Horenstein; Abhijit R Kulkarni; Clare Stokes; Lu W Corrie; Cheol-Young Maeng; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

9.  Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes.

Authors:  Jens Halvard Grønlien; Monika Håkerud; Hilde Ween; Kirsten Thorin-Hagene; Clark A Briggs; Murali Gopalakrishnan; John Malysz
Journal:  Mol Pharmacol       Date:  2007-06-12       Impact factor: 4.436

10.  A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors.

Authors:  Marijke Brams; Anshul Pandya; Dmitry Kuzmin; René van Elk; Liz Krijnen; Jerrel L Yakel; Victor Tsetlin; August B Smit; Chris Ulens
Journal:  PLoS Biol       Date:  2011-03-29       Impact factor: 8.029

View more
  8 in total

1.  Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Authors:  Clare Stokes; Sumanta Garai; Abhijit R Kulkarni; Lucas N Cantwell; Colleen M Noviello; Ryan E Hibbs; Nicole A Horenstein; Khalil A Abboud; Ganesh A Thakur; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

2.  A Computational Analysis of the Factors Governing the Dynamics of α7 nAChR and Its Homologs.

Authors:  Alican Gulsevin; Jens Meiler; Nicole A Horenstein
Journal:  Biophys J       Date:  2020-09-16       Impact factor: 4.033

3.  The effect of the α7nAChR agonist on Wnt/β-catenin signaling in osteoporosis.

Authors:  Feng Ma; Xiaohai Luo; Jingzu Ma; Ziyang Yang; Zhanchuan Yao; Xiaojun Luo
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

4.  Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation.

Authors:  Maria Chiara Pismataro; Nicole A Horenstein; Clare Stokes; Marta Quadri; Marco De Amici; Roger L Papke; Clelia Dallanoce
Journal:  Eur J Med Chem       Date:  2020-07-28       Impact factor: 6.514

5.  Stable desensitization of α7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site.

Authors:  Maria Chiara Pismataro; Nicole A Horenstein; Clare Stokes; Clelia Dallanoce; Ganesh A Thakur; Roger L Papke
Journal:  Eur J Pharmacol       Date:  2021-05-15       Impact factor: 5.195

6.  The Allosteric Activation of α7 nAChR by α-Conotoxin MrIC Is Modified by Mutations at the Vestibular Site.

Authors:  Alican Gulsevin; Roger L Papke; Clare Stokes; Hue N T Tran; Aihua H Jin; Irina Vetter; Jens Meiler
Journal:  Toxins (Basel)       Date:  2021-08-10       Impact factor: 4.546

Review 7.  In Silico Modeling of the α7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling.

Authors:  Alican Gulsevin; Roger L Papke; Nicole Horenstein
Journal:  Mini Rev Med Chem       Date:  2020       Impact factor: 3.862

Review 8.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.